International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology
- PMID: 37624384
- PMCID: PMC10547645
- DOI: 10.1007/s00259-023-06406-x
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology
Abstract
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. The merged International Society for Magnetic Resonance in Medicine (ISMRM) is an international, nonprofit, scientific association whose purpose is to promote communication, research, development, and applications in the field of magnetic resonance in medicine and biology and other related topics and to develop and provide channels and facilities for continuing education in the field.The ISMRM was founded in 1994 through the merger of the Society of Magnetic Resonance in Medicine and the Society of Magnetic Resonance Imaging. SNMMI, ISMRM, and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine and/or magnetic resonance imaging. The SNMMI, ISMRM, and EANM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and/or magnetic resonance imaging and to improve the quality of service to patients throughout the world. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice guideline, representing a policy statement by the SNMMI/EANM/ISMRM, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI, ISMRM, and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging and magnetic resonance imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by those entities not providing these services is not authorized. These guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNMMI, the ISMRM, and the EANM caution against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine includes both the art and the science of the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.
Keywords: Consensus; EANM; ISMRM; MRI; Oncology; PET; PETMR; SNMMI.
© 2023. The Author(s).
Conflict of interest statement
Author PVH has IIS grants from: Bayer Switzerland, Roche Pharmaceuticals, Siemens Healthineers, GE Healthcare and Point Biopharma. Author PVH has an Industry Sponsored Theranostic Trial: AAA. Author PVH has speaker fees and travel support from Siemens Healthineers and GE Healthcare. Author PVH has speaker fees from: Ontario Association of Radiologists and JCA PET/CT course. Author PVH receives editor fee from Springer Nature and reviewer compensation from Wellcome Trust. Author PVH receives strategic panel advisory compensation and travel support from the German Cancer Center. Author HA is co-founder and part-time employee of Antaros Medical AB, Mölndal, Sweden. He also owns stocks in Antaros Medical. Author SH received speaker honoraria from GE Healthcare and HERMES Medical Solutions. There are no other conflicts of interest with regard to the work in the manuscript. Author TH has grant funding to the institution from Clovis Oncology, Philips, GE Healthcare, Lantheus, Janssen, the Prostate Cancer Foundation, and the National Cancer Institute (R01CA235741 and R01CA212148). He received personal fees from Ipsen, Bayer and BlueEarth Diagnostics, and received fees from and has an equity interest in RayzeBio and Curium. Author MWH received grants and speaker honoraria from GE Healthcare, a fund by the Alfred and Annemarie von Sick legacy and a grant from the clinical research priority program (CRPP) Artificial Intelligence in Oncological Imaging Network of the University of Zurich. Author AI is an unpaid consultant to GE Healthcare and Lantheus, paid consultant to Amgen, IRE, Curium (EU), ITM, Novartis, Rayzebio and Telix, and a member of the scientific advisory board at Clarity Pharmaceuticals and Alpha9 Theranostics. Mayo Clinic receives funding from Novartis, Pfizer, MedTrace, Clarity, Clovis, and ViewPoint/Perspective for research conducted by author GBJ. Mayo Clinic receives funding for consulting with Pfizer, Novartis, Curium, Blue Earth, AstraZeneca and Lantheus conducted by author GBJ. Companies founded by author GBJ include Nucleus RadioPharma and The Green Clinic. Mayo Clinic and author GBJ hold patents pending on radionuclide theragnostic technologies. Author UM is a consultant for POINT Biopharma inc. Author HHQ has received research grants from Siemens Healthcare GmbH, Erlangen. Author BS has received speaker honoraria from SIEMENS Healthineers and is a member of the policy and regulatory affairs committee of EANM. Author GZ has received research grants from GE Healthcare and Bayer, consulting fees from Biogen, and equity in Subtle Medical, Inc. Author KH reports personal fees from: Bayer, SIRTEX, Adacap, Curium, Endocyte, IPSEN, Siemens Heatlhineers, GE Healthcare, Amgen, Fusion, Immedica, Onkowissen.de, Novartis, Molecular Partners, ymabs, Aktis Oncology, Theragnostics, Pharma15, Debiopharma, AstraZeneca and Janssen. Author KH also has personal fees and other from Sofie Biosciences, non-financial support from ABX and grants and personal fees from BTG. Authors RB, RCDB, AK, IA, and LU declared no conflict of interest.
Figures

Similar articles
-
SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0.J Nucl Med. 2025 Jun 6;66(Suppl 2):S45-S60. doi: 10.2967/jnumed.124.268754. J Nucl Med. 2025. PMID: 39419552
-
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2323-2341. doi: 10.1007/s00259-022-05780-2. Epub 2022 Apr 4. Eur J Nucl Med Mol Imaging. 2022. PMID: 35376991 Free PMC article.
-
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0.J Nucl Med. 2021 Jan;62(1):99-110. doi: 10.2967/jnumed.120.254110. J Nucl Med. 2021. PMID: 33334912 Free PMC article.
-
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.Breast. 2024 Dec;78:103806. doi: 10.1016/j.breast.2024.103806. Epub 2024 Sep 12. Breast. 2024. PMID: 39303572 Free PMC article. Review.
-
Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma.J Am Coll Surg. 2007 Aug;205(2):362-376. doi: 10.1016/j.jamcollsurg.2007.02.057. J Am Coll Surg. 2007. PMID: 17660085 Review.
Cited by
-
Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.Chin J Cancer Res. 2023 Oct 30;35(5):470-482. doi: 10.21147/j.issn.1000-9604.2023.05.05. Chin J Cancer Res. 2023. PMID: 37969954 Free PMC article.
-
Whole-body MRI Versus [ 18 F]FDG PET/CT in Diagnosing and Monitoring Plasmacytomas : A Comparative Study.Clin Nucl Med. 2025 Aug 1;50(8):695-706. doi: 10.1097/RLU.0000000000005954. Epub 2025 May 16. Clin Nucl Med. 2025. PMID: 40375446 Free PMC article.
-
PET/MRI is superior to PET/CT in detecting oesophago and gastric carcinomas: a meta-analysis.Cancer Imaging. 2025 Apr 7;25(1):50. doi: 10.1186/s40644-025-00871-3. Cancer Imaging. 2025. PMID: 40197531 Free PMC article.
-
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?Ann Nucl Med. 2025 May;39(5):407-423. doi: 10.1007/s12149-025-02022-x. Epub 2025 Mar 11. Ann Nucl Med. 2025. PMID: 40069442 Free PMC article. Review.
-
Editorial: Global excellence in nuclear medicine: North America.Front Med (Lausanne). 2023 Oct 25;10:1300179. doi: 10.3389/fmed.2023.1300179. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37954553 Free PMC article. No abstract available.
References
-
- Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95. - PubMed
-
- Pichler BJ, Judenhofer MS, Catana C, Walton JH, Kneilling M, Nutt RE, et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med. 2006;47:639–647. - PubMed